Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

Join Prof. Jessica Lin as she explores key strategies for managing ALK+ NSCLC while prioritizing long-term patient safety

Speaker : Prof. Jessica Lin

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr Vijay Agarwal ,Dr. Ananth Pai ,Dr. Sai Vivek ,Dr. Harish P

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr. Harish P ,Dr. Sai Vivek ,Dr. Ananth Pai ,Dr Vijay Agarwal

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr. Vijay Agarwal ,Dr. Ananth Pai ,Dr. Sai Vivek ,Dr. Harish P

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr. Harish P ,Dr. Sai Vivek ,Dr. Ananth Pai ,Dr Vijay Agarwal

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr Vijay Agarwal ,Dr. Ananth Pai ,Dr. Sai Vivek ,Dr. Harish P

Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2

Explore the impact of CDK4/6 inhibition in HR+/HER2- metastatic breast cancer, drawing insights from the pivotal PALOMA-2 study presented by Dr. Bhavna Parikh.

Speakers : Dr Bhavna Parikh

The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.

Discover the comprehensive impact of CDK4/6 inhibition in HR+/HER2- metastatic breast cancer, with key insights from the PALOMA-2 study presented by Dr. Bhavna Parikh.

Speakers : Dr Bhavna Parikh

Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.

Explore the multifaceted advantages of CDK4/6 inhibitors in HR+/HER2- breast cancer, based on the PALOMA-2 study, in this insightful session with Dr. Bhavna Parikh.

Speakers : Dr Bhavna Parikh

An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.

A detailed discussion on the benefits of using CDK4/6 inhibitors in HR+/ HER2-aBC in clinical trials.

Speakers : Dr. Bhavna Parikh

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV

The webinar gives insights into the role of pazopanib in managing renal cell carcinoma.

Speakers : Dr. Yogesh Kumar ,Dr. Pankaj Goyal ,Dr. Jatin Sarin ,Dr. Ankur Punia


Recommended News For You

An FDA panel supports the use of CAR T-cell therapy earlier in the treatment of multiple myeloma.

recognizing the mechanism by which the replication of the host cell is outperformed by the skin cancer virus.

FDA Expands Durvalumab Label to Operable Lung Cancer

DNA origami offers more accurate imaging in the fight against pancreatic cancer

The New Canadian Guidelines for Drinking at High Risk, AUD.

Quality of Life Similar With Proton Beam Therapy vs IMRT for Prostate Cancer

Long-term study links chronic conditions in midlife to higher cancer risk and mortality

Recommended Articles For You

Digital Oncology: How Remote Monitoring and Mobile Health Are Transforming Cancer Care 

RDW-CV vs. MCV: Knowing the Difference Can Help You Better Understand Your Health  

Screening Efficacy, Molecular Precision, and Therapeutic Revolutions in Lung Cancer 2025 

Genetic Screening: A Game Changer in Cancer Prevention 
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In leukemia, allogeneic HCT is beneficial following primary induction failure.

2.

Team finds broken 'brake' on cancer mutation machine.

3.

Omega Fatty Acid Changes Tied to Lower Proliferation Rate in Early Prostate Cancer

4.

Prostate cancer screening program beneficial in top decile of polygenic risk score

5.

Talk About Medication Costs, Bringing Back Touch, and Understanding From Dish Tumors.

1.

New Research on Craniopharyngioma 

2.

What Is May-Hegglin Anomaly? Understanding this Rare Blood Disorder

3.

A Closer Look at White Blood Cells in Urine: Uncovering the Causes and Treatments

4.

The Expanding Horizon of PSMA: A Comparative Clinical Review of Theranostics in Prostate Cancer and Beyond

5.

The Mysterious World of Petechiae: Exploring Causes and Treatments

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Navigating the Complexities of Ph Negative ALL - Part VI

2.

A New Era in Managing Cancer-Associated Thrombosis

3.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V

4.

Navigating the Complexities of Ph Negative ALL - Part XV

5.

Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot